Software Documentation and Cybersecurity Content in Device Submissions

1. Key takeaways

Devices containing software must submit software documentation — covering the software description, software lifecycle activities, and risk management — together with a cybersecurity section. At the same time, software-based devices (SaMD) are subject to a dedicated labeling provision, 21 CFR 801.50, and fall under 21 CFR Part 830 for UDI and GUDID data submission. The practical picture is that software cuts across the submission rather than occupying one section of it: the same version decisions, risk decisions, and change decisions echo through the documentation, the labeling, and the UDI data. Planning those decisions together is what keeps the software content of the dossier consistent from first section to last.

• Software documentation is organized around the description, the lifecycle activities, and risk management, with AAMI/IEC 62304 as the recognized lifecycle standard.
• The cybersecurity section follows the framework of the FDA cybersecurity guidance: risk assessment, controls, residual risk acceptance, and postmarket management.
• SaMD carries its own labeling rule at 21 CFR 801.50; the assumption that software needs no labeling is wrong.
• Software versioning is tied to the UDI production identifier, and adaptive algorithms need a stated change control approach at submission.

2. Legal basis

The instruments listed below, as cited in the source material, cover the labeling provision, the UDI framework, the statutory definition that captures software, the cybersecurity guidance, and the recognized standards.

3. Expert insights

Insight one: the United States has no separate SaMD market pathway, but it does have a separate labeling clause.

The category terms defined in FD&C Act section 201(h) do not list software separately, yet software is regulated as a device in FDA practice, and there is a dedicated labeling provision at 21 CFR 801.50. This is a direct refutation of the assumption that software does not need labeling. A submission that treats the software product as exempt from labeling obligations on grounds of its intangibility has misread the provision, and the error tends to be discovered exactly where intangible products meet the market — on the packaging, the website, and the instructions that reach the user. Checking the labeling provision at the start of the project costs nothing; discovering the gap after launch costs a correction campaign.

Insight two: the center of gravity of the cybersecurity section is premarket risk management plus postmarket patch management.

Following the framework of the FDA cybersecurity guidance, the submission must address the cybersecurity risk assessment, the control measures that have been implemented, the justification for accepting the residual risks, and the postmarket plan for vulnerability monitoring and patch management. The last element is especially important, because it determines whether subsequent software changes require a new premarket submission. A well-argued postmarket plan is therefore not a closing formality: it is the instrument that defines how much of the future maintenance of the product happens inside the cleared envelope and how much of it reopens review.

Insight three: software version changes are tied to the production identifier of the UDI.

Under 21 CFR Part 830, a UDI may be composed of the device identifier (DI) plus the production identifier (PI), and the software version is one element of the PI. The software version management strategy therefore directly affects how often UDI and GUDID data must be updated. A versioning policy chosen for engineering convenience can multiply data maintenance work downstream, while a policy chosen with the PI rules in view keeps the identifier stable where stability is allowed and changes it only where the rules require. Deciding this once, early, spares the GUDID record a churn of corrections later.

Insight four: change management for AI and machine learning products must be explained at submission.

For products containing adaptive algorithms, FDA’s concern is how algorithm updates are kept under control. The submission should state a predetermined change control plan, so that not every algorithm update turns into a new premarket submission. The plan is what converts an open-ended regulatory exposure into a bounded one: within the described envelope, updates proceed under the stated controls; outside it, the ordinary pathway applies and everyone knows it in advance. Writing the plan late, after the algorithm has already drifted, forfeits exactly this benefit, which is why it belongs in the dossier rather than in the roadmap deck.

4. Practical recommendations

• Organize the software documentation according to the lifecycle processes of AAMI/IEC 62304, matched to the safety classification.
• Build the cybersecurity section along four segments: risk assessment, control measures, residual risk, and postmarket management.
• Prepare the labeling according to 21 CFR 801.50; do not reuse the labeling template intended for physical devices.
• Settle the UDI and software version management strategy at the dossier stage.
• For products containing AI or algorithms, prepare the predetermined change control plan in parallel with the submission.

5. Verification checklist

• □ The software documentation has been organized by lifecycle process, matched to the safety classification
• □ The cybersecurity section contains all four segments: risk assessment, control measures, residual risk, and postmarket management
• □ The labeling has been prepared according to 21 CFR 801.50
• □ The UDI and software version management strategy has been settled
• □ A change control plan has been prepared for products containing AI or algorithms
• □ The standard versions have been verified against the FDA-recognized consensus standards database

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com